Status:
COMPLETED
Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment
Lead Sponsor:
Sohag University
Conditions:
Braest Cancer
Dry Eye
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impa...
Detailed Description
Aromatase inhibitors (AI) therapy is an important treatment for estrogen receptor-positive breast cancer (BC). This work evaluated the eye anterior segment changes in estrogen-dependent BC after hormo...
Eligibility Criteria
Inclusion
- Females diagnosed with breast cancer
Exclusion
- uncontrolled diabetes , auto immune diseases
Key Trial Info
Start Date :
June 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06924229
Start Date
June 1 2024
End Date
January 1 2025
Last Update
April 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag university
Sohag, Egypt